AbbVie

AbbVie, Genmab's lymphoma drug Epkinly snags FDA approval in heated blood cancer race
AbbVie, Genmab's lymphoma drug Epkinly snags FDA approval in heated blood cancer race
Fierce Pharma
AbbVie
Genmab
FDA
anti-CD20
epcoritamab
diffuse large B-cell lymphoma
Epkinly
Flag link:
AbbVie's Rinvoq scores its 7th FDA nod, this one for Crohn's disease
AbbVie's Rinvoq scores its 7th FDA nod, this one for Crohn's disease
Fierce Pharma
AbbVie
FDA
Rinvoq
Crohn's Disease
Humira
Flag link:
Allergan's new skin-smoothing product gets FDA nod—with novel delivery mechanism
Allergan's new skin-smoothing product gets FDA nod—with novel delivery mechanism
Fierce Pharma
AbbVie
FDA
Skinvive
Juvederm
aesthetics
Flag link:
The waxing and waning of the speedy approval
The waxing and waning of the speedy approval
EP Vantage
FDA
drug approvals
accelerated approvals
AbbVie
AstraZeneca
Bayer
Bristol Myers Squibb
JNJ
Merck
Merck KGaA
Novartis
Pfizer
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
2 Things About AbbVie That Investors Are Ignoring
2 Things About AbbVie That Investors Are Ignoring
Motley Fool
AbbVie
immunology
aesthetics
Neuroscience
Flag link:
AbbVie, Bristol Myers vied for Prometheus before Merck bought it
AbbVie, Bristol Myers vied for Prometheus before Merck bought it
Crain's Chicago Business
Merck
Prometheus Biosciences
M&A
AbbVie
Bristol Myers Squibb
Flag link:
Where Will AbbVie Be in 5 Years?
Where Will AbbVie Be in 5 Years?
Motley Fool
AbbVie
Humira
biosimiliars
Flag link:
As Humira biosims take hold, longtime AbbVie CEO Richard Gonzalez talks succession plans
As Humira biosims take hold, longtime AbbVie CEO Richard Gonzalez talks succession plans
Fierce Pharma
AbbVie
Pharma CEOs
Richard Gonzalez
Humira
biosimilars
Flag link:
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access
Fierce Pharma
AbbVie
Amgen
Bristol Myers Squibb
Eli Lilly
Gilead Sceinces
JNJ
Merck
Pfizer
Regeneron
patents
activists
Flag link:
AAN 2023: AbbVie highlights Qulipta’s edge over oral migraine prophylaxis
AAN 2023: AbbVie highlights Qulipta’s edge over oral migraine prophylaxis
Clinical Trials Arena
AbbVie
Qulipta
chronic migraine
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma’s biggest spenders revealed: 2022 edition
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
M&A
R&D
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Novartis
Pfizer
Roche
Sanofi
Flag link:
FDA expands Qulipta indication to include chronic migraine prevention
FDA expands Qulipta indication to include chronic migraine prevention
Healio
AbbVie
migraine
FDA
CGRP blockers
Qulipta
Flag link:
In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog
In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog
Fierce Pharma
Novartis
Cosentyx
AbbVie
Humira
hidradenitis suppurativa
UCB Pharma
Flag link:
AbbVie-sponsored docuseries goes beyond the before and after
AbbVie-sponsored docuseries goes beyond the before and after
Medical Marketing and Media
AbbVie
pharma marketing
plastic surgery
aesthetics
Flag link:
AbbVie removes two approvals for blood cancer drug Imbruvica
AbbVie removes two approvals for blood cancer drug Imbruvica
BioPharma Dive
AbbVie
Imbruvica
cancer
Flag link:
AbbVie knocks down earnings forecast due to IPR&D charge
AbbVie knocks down earnings forecast due to IPR&D charge
Fierce Biotech
AbbVie
R&D
Flag link:
Spotlight – following Humira in hidradenitis suppurativa
Spotlight – following Humira in hidradenitis suppurativa
EP Vantage
AbbVie
Humira
hidradenitis suppurativa
UCB Pharma
Bimzelx
MoonLake Immunotherapeutics
Flag link:

Pages